Arrestin2 modulates and rogen receptor activation

Oncogene

Volumn 34, Issue 24, 2015, Pages 3144-3151

  Purayil, H T ^a   Zhang, Y ^a   Dey, A ^a   Gersey, Z ^a   Espana Serrano, L ^a   Daaka, Y ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA ARRESTIN 2; FATTY ACID SYNTHASE; FK 506 BINDING PROTEIN; PROSTATE SPECIFIC ANTIGEN; AR PROTEIN, HUMAN; ARRESTINS; BETA-ARRESTIN; PROTEIN BINDING; RECEPTORS, ANDROGEN;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; DISEASE COURSE; DISTANT METASTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; TUMOR INVASION; ANIMALS; CELLS, CULTURED; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETICS; HUMANS; MALE; METABOLISM; MICE; MICE, SCID; NEOPLASMS, HORMONE-DEPENDENT; PATHOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RESPONSE ELEMENTS;

ANIMALS; ARRESTINS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, SCID; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN BINDING; RECEPTORS, ANDROGEN; RESPONSE ELEMENTS;

EID: 84930819511     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.252     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Attard G, Richards J, de Bono JS. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011; 17: 1649-1657.
3. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8: 440-448.
4. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351: 1488-1490.
5. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
6. Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 2011; 57: 1366-1375.
7. Lamont KR, Tindall DJ. Androgen regulation of gene expression. Adv Cancer Res 2010; 107: 137-162.
8. Matsumoto T, Sakari M, Okada M, Yokoyama A, Takahashi S, Kouzmenko A et al. The androgen receptor in health and disease. Annu Rev Physiol 2013; 75: 201-224.
9. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-839.
10. Lefkowitz RJ, Whalen EJ. Arrestins: traffic cops of cell signaling. Curr Cin Cell Biol 2004; 16: 162-168.
11. Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ. Arrestin inhibits NF-B activity by means of its interaction with the NF-B inhibitor IB. Proc Natl Acad Sci USA 2004; 101: 8603-8607.
12. Chen W, Kirkbride KC, How T, Nelson CD, Mo J, Frederick JP et al. rrestin2 mediates endocytosis of type III TGF-receptor and down-regulation of its signaling. Science 2003; 301: 1394-1397.
13. Ma L, Pei G. rrestin signaling and regulation of transcription. J Cell Sci 2007; 120: 213-218.
14. Lakshmikanthan V, Zou L, Kim JI, Michal A, Nie Z, Messias NC et al. Identification of Arrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci USA 2009; 106: 9379-9384.
15. Chen W, ten Berge D, Brown J, Ahn S, Hu LA, Miller WE et al. Dishevelled 2 recruits rrestin2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science 2003; 301: 1391-1394.
16. Wilbanks AM, Fralish GB, Kirby ML, Barak LS, Li YX, Caron MG. rrestin2 regulates zebrafish development through the hedgehog signaling pathway. Science 2004; 306: 2264-2267.
17. Scott MG, Le Rouzic E, Perianin A, Pierotti V, Enslen H, Benichou S et al. Differential nucleocytoplasmic shuttling of rrestins: characterization of a leucine-rich nuclear export signal in rrestin2. J Biol Chem 2002; 277: 37693-37701.
18. Wang P, Wu Y, Ge X, Ma L, Pei G. Subcellular localization of rrestins is determined by their intact N domain and the nuclear export signal at the C terminus. J Biol Chem 2003; 278: 11648-11653.
19. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of rrestin1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 2006; 103: 1492-1497.
20. Zou L, Yang R, Chai J, Pei G. Rapid xenograft tumor progression in rrestin1 transgenic mice due to enhanced tumor angiogenesis. FASEB J 2008; 22: 355-364.
21. Wang LG, Su BH, Du JJ. Expression of rrestin1 in gastric cardiac adenocarcinoma and its relation with progression. Asian Pac J Cancer Prev 2012; 13: 5671-5675.
22. Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, Shenoy SK et al. Functional specialization of rrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci USA 2007; 104: 12011-12016.
23. Gregory CW, Johnson RT Jr. , Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61: 2892-2898.
24. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002; 9: 601-610.
25. Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE. Androgen receptor and invasion in prostate cancer. Cancer Res 2008; 68: 1128-1135.
26. Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W et al. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol 2012; 10: 29.
27. Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002; 60: 132-138; discussion 138-139.
28. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
29. Chen Y, Liu Z, Halterman DA. Molecular determinants of resistance activation and suppression by phytophthora infestans effector IPI-O. PLoS Pathogen 2012; 8: e1002595.
30. Boorjian SA, Heemers HV, Frank I, Farmer SA, Schmidt LJ, Sebo TJ et al. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer 2009; 16: 123-137.
31. Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: Measurement by color video image analysis. Cancer Res 1994; 54: 4096-4102.
32. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC et al. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 2009; 15: 39-47.
33. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995; 55: 3068-3072.
34. Hoeppner CZ, Cheng N, Ye RD. Identification of a nuclear localization sequence in rrestin1 and its functional implications. J Biol Chem 2012; 287: 8932-8943.
35. Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M et al. A nuclear function of rrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell 2005; 123: 833-847.
36. Shenoy SK, Han S, Zhao YL, Hara MR, Oliver T, Cao Y et al. rrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. Oncogene 2012; 31: 282-292.
37. Mo W, Zhang L, Yang G, Zhai J, Hu Z, Chen Y et al. Nuclear rrestin1 functions as a scaffold for the dephosphorylation of STAT1 and moderates the antiviral activity of IFN. Mol Cell 2008; 31: 695-707.
38. Liu YN, Liu Y, Lee HJ, Hsu YH, Chen JH. Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol Cell Biol 2008; 28: 7096-7108.
39. Rosano L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F et al. rrestin1 is a nuclear transcriptional regulator of endothelin-1-induced-catenin signaling. Oncogene 2013; 32: 5066-5077.
40. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: Considerations and practical approach. Nat Protoc 2009; 4: 309-324.
41. Lang SH, Sharrard RM, Stark M, Villette JM, Maitland NJ. Prostate epithelial cell lines form spheroids with evidence of glandular differentiation in threedimensional Matrigel cultures. Br J Cancer 2001; 85: 590-599.
42. Harma V, Virtanen J, Makela R, Happonen A, Mpindi JP, Knuuttila M et al. A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One 2010; 5: e10431.
43. Khaitan D, Chandna S, Arya MB, Dwarakanath BS. Establishment and characterization of multicellular spheroids from a human glioma cell line; implications for tumor therapy. J Transl Med 2006; 4: 12.